Harmony Biosciences (HRMY) Misses Q4 EPS by 29c

Harmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.57, $0.29 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $243.8 million versus the consensus estimate of $239.23 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• AeroVironment (AVAV) Tops Q4 EPS by 36c
• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Cheetah Net ends at-the-market stock sales agreement with AC Sunshine